Clinical Trial Update: Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating tolerability of rivastigmine when switching from the oral formulation to a transdermal patch in Alzheimer's disease. Results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon (rivastigmine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Dementia | Phase 4 | Status: COMPLETED | Results posted: 2016-11-10